Myriad Genetics Inc (NASDAQ:MYGN) delivered a fourth-quarter financial performance that notably exceeded analyst expectations, sparking a significant positive reaction in its stock price. The molecular diagnostics company reported results for the quarter ended December 31, 2025, showcasing improved execution and providing a steady outlook for the year ahead.
Earnings and Revenue Versus Estimates
The company’s top and bottom-line results for Q4 2025 surpassed Wall Street forecasts, a key driver behind the market's enthusiastic response.
- Revenue: Myriad reported quarterly revenue of $209.8 million. This figure was essentially flat compared to the $210.6 million reported in Q4 2024. However, it came in above the analyst consensus estimate of approximately $211.5 million.
- Earnings Per Share (EPS): The beat on profitability was more pronounced. Myriad posted a non-GAAP EPS of $0.04, a substantial upside compared to the analyst estimate for a loss of ($0.0149) per share. On a GAAP basis, the company reported a net loss of $7.9 million, or ($0.08) per share.
Market Reaction and Price Action
The market's reaction to this earnings report has been decisively positive. Following the announcement, Myriad Genetics' stock experienced a sharp upward move in after-hours trading, rising approximately 19.6%. This surge indicates investor relief and optimism, likely fueled by the earnings beat and the company's reaffirmed guidance after a period of significant stock price pressure over the past month.
Key Highlights from the Earnings Report
Beyond the headline numbers, management highlighted several areas of operational progress and strategic positioning.
- Volume Growth in Core Areas: Test volumes grew 2% year-over-year to 382,000. Key products showed solid volume increases:
- Hereditary cancer testing volumes grew 9%.
- Prolaris prostate cancer test volumes grew 12%.
- GeneSight mental health test volumes grew 9%.
- Improved Financial Discipline: Adjusted operating expenses decreased by $7.0 million year-over-year to $139.0 million, reflecting ongoing cost management efforts. The company also generated positive adjusted free cash flow of $11.9 million for the quarter.
- Pipeline and Launches: CEO Sam Raha emphasized 2026 as a milestone year with three planned test launches: a targeted alpha launch for the Precise MRD test in breast cancer, and full commercial launches of an AI-enabled Prolaris test and the FirstGene prenatal screen.
Forward Guidance and Analyst Expectations
Myriad Genetics reiterated its full-year 2026 financial guidance, which aligns closely with existing analyst projections and suggests a year of stabilized growth.
- The company expects 2026 revenue between $860 million and $880 million. The midpoint of this range ($870 million) is very close to the current analyst sales estimate of approximately $884.5 million.
- For the first quarter of 2026, management anticipates revenue between $200 million and $203 million, representing 2% to 4% growth over Q1 2025. This outlook accounts for current business trends and an unfavorable year-over-year comparison in prenatal testing.
The reiterated guidance, following a quarter of execution that beat estimates, appears to have bolstered investor confidence in the company's near-term trajectory.
For a detailed breakdown of future quarterly estimates and historical earnings performance, you can review more data on Myriad Genetics' earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an endorsement of any investment strategy. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
